We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.46 | -0.93% | 49.00 | 42.19 | 50.80 | 49.595 | 48.97 | 49.48 | 1,113,911 | 05:00:11 |
From May 2019 to May 2024
By Matthew Dalton
PARIS--Sanofi S.A. on Friday said it will work with German biotech company Evotec AG to develop a new class of medicines to treat diabetes.
Sanofi could pay Evotec up to EUR300 million ($327.8 million) for hitting various drug development milestones, plus additional royalties on net sales of the drugs.
The collaboration will use human stem cells to develop drugs that bolster "Beta" cells, which release insulin and become impaired in people with diabetes. The drugs could reduce the need for diabetes patients to inject themselves with insulin, Sanofi said.
Write to Matthew Dalton at matthew.dalton@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
